Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,385.52 -32.16 -0.22%
TOPIX 1,164.41 -2.14 -0.18%
HANG SENG 22,776.12 80.11 0.35%

Biogen Idec to Report Fourth Quarter & Year End 2012 Financial Results on January 28, 2013

  Biogen Idec to Report Fourth Quarter & Year End 2012 Financial Results on
  January 28, 2013

Business Wire

WESTON, Mass. -- January 14, 2013

Biogen Idec Inc. (NASDAQ: BIIB) today announced it will report fourth quarter
and year end 2012 financial results on Monday, January 28, 2013, before the
financial markets open.

Following the release of the financials, the Company will host a live webcast
where Biogen Idec management will discuss the financial results, at 8:00 am
ET. To access the live webcast, please go to the investor relations section of
Biogen Idec’s website at Following the live webcast, an
archived version of the call will be available at the same URL, for one month.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world’s oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labeling, press releases and additional information about the company, please


Biogen Idec
Karen Jewell, 781-464-2442
Investor Relations
Sponsored Links
Sponsored Links